© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Expert oncologists Tanios Bekaii-Saab, MD; Anthony El-Khoueiry, MD; Pierre Gholam, MD; Arndt Vogel, MD; and Mark Yarchoan, MD, review data from ASCO 2022 and discuss updates in the management of HCC.
June 29th 2022
Centering discussion on a patient with early/intermediate-stage HCC, expert panelists consider the roles of transplant, resection, and adjuvant therapy, respectively.
A brief discussion on the risks of neoadjuvant immunotherapy in early-/intermediate-stage HCC with regard for liver transplantation candidacy.
July 6th 2022
Expert oncologists consider when it would be appropriate to use neoadjuvant therapy for early-/intermediate-stage hepatocellular carcinoma.
Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC
July 13th 2022
Panelists consider the role of systemic therapy in patients with intermediate-stage HCC who are ineligible for locoregional therapy.
A brief review of predictive and prognostic biomarker needs in hepatocellular carcinoma, followed by discussion on screening and detection.
July 20th 2022
Centering discussion on a patient with advanced-stage HCC, expert panelists discuss the frontline use of atezolizumab + bevacizumab as a standard of care.
Shared insight on combination durvalumab + tremelimumab as frontline therapy for advanced HCC in the context of data from the HIMALAYA trial.
July 27th 2022
Taking into account respective data from IMbrave150 and HIMALAYA, experts consider how they might select frontline therapy for advanced HCC.
Expert panelists briefly review how a patient’s hepatitis status may influence treatment selection for advanced hepatocellular carcinoma.
August 3rd 2022
Comprehensive insight on the selection and use of frontline tyrosine kinase inhibitors for patients with advanced hepatocellular carcinoma.
Before closing out their discussion on frontline therapy for advanced HCC, expert panelists review other novel combinations under investigation.
August 10th 2022
Centering discussion on a patient with advanced HCC, expert oncologists consider which agents they would use in the second line following lenvatinib failure.
Shared insight on which factors help to inform selection of second-line therapy for patients with advanced HCC following lenvatinib failure.
August 17th 2022
Expert panelists consider which therapy they would use following failure of atezolizumab + bevacizumab in advanced hepatocellular carcinoma.
Comprehensive insight on later-line immunotherapy and combination strategies available for patients with advanced hepatocellular carcinoma.